NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low on Insider Selling

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) hit a new 52-week low during trading on Thursday following insider selling activity. The company traded as low as $22.34 and last traded at $22.79, with a volume of 2317943 shares traded. The stock had previously closed at $25.63.

Specifically, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total transaction of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. This trade represents a 15.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Upgrades and Downgrades

NAMS has been the topic of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Royal Bank Of Canada cut their price objective on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.73.

NewAmsterdam Pharma News Roundup

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $52 price target. Other analysts also maintain positive views, including BMO Capital Markets at $58, Jefferies at $45 and RBC at $50, supporting the longer-term outlook for NAMS. HC Wainwright rating report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests short selling is not a meaningful explanation for the recent decline, although the data may reflect an incomplete or anomalous report. NewAmsterdam Pharma market data
• Neutral Sentiment: Analyst reports discussing NAMS alongside Amgen, Dyne Therapeutics and Ionis Pharmaceuticals did not identify a new company-specific catalyst. Broader healthcare-sector commentary may influence sentiment but provides limited direct information about NewAmsterdam’s business. Healthcare analyst report
• Negative Sentiment: Director John W. Smither sold 1,600 shares for approximately $40,512, reducing his direct holdings by 15.44%. Although the sale may have been for personal reasons, it can reinforce investor caution during a period of market weakness. SEC insider transaction filing
• Negative Sentiment: NAMS reached a new one-year low following the insider-sale disclosure, signaling continued technical and investor-pressure concerns. The company also remains loss-making; its latest quarterly EPS missed expectations, and analysts forecast a full-year loss of about $1.82 per share. New one-year low report

NewAmsterdam Pharma Trading Down 4.1%

The stock has a fifty day moving average of $28.84 and a two-hundred day moving average of $31.27. The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of -10.12 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NAMS. Wells Fargo & Company MN lifted its position in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares in the last quarter. KBC Group NV acquired a new stake in NewAmsterdam Pharma in the 1st quarter valued at about $37,000. Navalign LLC acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at about $46,000. AdvisorNet Financial Inc bought a new position in shares of NewAmsterdam Pharma in the first quarter worth about $82,000. Finally, Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $85,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.